American Diabetes Association 81st Scientific Sessions (ADA 2021)

Sotagliflozin SCOREs in T2D patients with kidney disease

Pearl Toh, 20210731143500

The dual SGLT1/2* inhibitor sotagliflozin significantly lowers the risk of the composite outcome of cardiovascular (CV) deaths, hospitalizations for heart failure (HHF), and urgent visits for heart failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), regardless of albuminuria status, according to the SCORED trial presented at ADA 2021.

Tirzepatide SURPASSes semaglutide for HbA1c reductions, weight loss

Roshini Claire Anthony, 20210730180001

In patients with type 2 diabetes (T2D), once-weekly doses of the dual glucose-dependent insulinotropic polypeptide–GLP-1* receptor agonist tirzepatide for 40 weeks resulted in superior HbA_1c reductions compared with the GLP-1 receptor agonist semaglutide, according to results from the phase III SURPASS-2** trial presented at ADA 2021.

Efpeglenatide reduces MACE, kidney events in high-risk patients with T2D

Roshini Claire Anthony, 20210723180001

In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.

Volagidemab improves glycaemic control in T1D patients

Audrey Abella, 20210722100000

Phase II data presented at ADA 2021 showed the potential of the GRA* volagidemab to improve glycaemic control in patients with type 1 diabetes (T1D).

Ertugliflozin improves glycaemic outcomes in patients with stage 3 CKD

Elaine Soliven, 20210721000000

Ertugliflozin significantly improves glycaemic outcomes in patients with type 2 diabetes (T2D) who have stage 3 chronic kidney disease (CKD), according to a subgroup analysis of the VERTIS CV* trial presented at ADA 2021.

Dorzagliatin a new hope for T2D

Audrey Abella, 20210719100000

In drug-naïve Chinese patients with type 2 diabetes (T2D), treatment with the first-in-class, glucose sensitizer dorzagliatin led to sustained glycaemic control, according to updated findings from the 52-week phase III SEED* study presented at ADA 2021.

iGlarLixi trumps biphasic insulin for glycaemic control, weight loss in poorly controlled T2D

Insulin glargine/lixisenatide combo drug trumps biphasic insulin in poorly controlled T2D

Pearl Toh, 20210716150000

Once-daily iGlarLixi is superior to twice-daily premixed biphasic insulin aspart 30 (BIAsp 30) in glycaemic control and reducing body weight, along with less risk of hypoglycaemia, in patients with suboptimally controlled type 2 diabetes (T2D) despite treatment with basal insulin plus oral antihyperglycaemic drugs (OADs), according to the SoliMix trial presented at ADA 2021.

Time-restricted eating for weight loss: The jury is still out

Elvira Manzano, 20210713090000

Time-restricted eating (TRE) could provide a modest 1–4 percent weight loss without cutting calories, says an expert. But whether the evidence on hand supports its use is still debatable.

SUSTAIN FORTE reinforces semaglutide 2.0 mg for poorly controlled T2D

Elvira Manzano, 20210709073000

The investigational 2.0-mg dose of semaglutide provided greater reductions in glycated haemoglobin (HbA1c) and body weight than semaglutide 1.0 mg in the phase IIIb SUSTAIN FORTE trial.

Semaglutide: Four STEPs ahead in obesity care

Semaglutide: Four STEPs ahead in weight loss management

Pearl Toh, 20210706150000

With four STEP* studies published on the profound impact that semaglutide 2.4 mg confers on weight loss, these indicate GLP-1 signalling as a powerful and effective target for obesity therapy and thus, usher in a new era for obesity care, said a leading expert during the ADA 2021 session.